Results 211 to 220 of about 9,804 (228)

O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir

Journal of Hepatology, 2015
H. Dvory-Sobol, D. Wyles, W. Ouyang, K. Chodavarapu, J. McNally, W. Cheng, S. Shafran, A. Mangia, C. Schwabe, M.D. Miller, H. Mo   +10 more
openaire   +1 more source

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Nature, 2010
David R Langley, Jin-hua Sun, Nicholas A Meanwell   +2 more
exaly  

Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A

Nature, 2015
David R Langley, Benjamin M Johnson, Nicholas A Meanwell   +2 more
exaly  

The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein

Virology, 2011
Choongho Lee, Ella H Sklan, Jeffrey S Glenn   +2 more
exaly  

Diphenylcarboxamides as Inhibitors of HCV Non-Structural Protein NS5a

Antiviral Research, 2010
Malcolm Carter, Bob Baxter, David Bushnell, Stuart Cockerill, Jo Chapman, Sally Fram, Emma Goulding, Mike Lockyer, Neil Mathews, Pilar Najarro, Dilupa Rupassara, James Salter, Elaine Thomas, Chris Wheelhouse, Jessica Borger, Kenneth Powell   +15 more
openaire   +1 more source

Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1

The Lancet Gastroenterology and Hepatology, 2018
Charles S Landis, Hadas Dvory-Sobol, K Rajender Reddy   +2 more
exaly  

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

Proceedings of the National Academy of Sciences of the United States of America, 2013
Jeremie guedj, Harel Dahari, Libin Rong
exaly  

In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6

Journal of Viral Hepatitis, 2019
Hadas Dvory-Sobol
exaly  

A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus

European Journal of Medicinal Chemistry, 2019
Chiung-Tong Chen, Jyh-Haur Chern
exaly  

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms

Journal of Medicinal Chemistry, 2017
Ling Tong, Wensheng Yu, Lei Chen
exaly